CDK9 (Cyclin-dependent kinase 9), is a serine/threonine kinase that forms the catalytic core of the positive transcription elongation factor b (P-TEFb). This enzyme is critical for stimulating transcription elongation of most protein coding genes, including key developmental and stimulus-responsive genes, by RNA polymerase II (RNAPII). CDK9 is not a typical Cdc-2 like kinase and it does not act in cell cycle regulation processes; rather, it acts in differentiation processes. Activity of CDK9 is dependent on binding to a regulatory cyclin subunit (cyclin T1, T2a or T2b) and it is further regulated through association with other modulators like c-myc, NF-kB, androgen receptor (AR) and Brd4. Targeting CDK9 with small molecule inhibitors represents a viable strategy for the treatment of several diseases, indicated especially by the deregulation of CDK9 activity in cancers, cardiac hypertrophy, HIV infections and pathological inflammation. CDK9 inhibitors have demonstrated good antitumoral activity in vitro.
|Tissue Type/Cancer Type|
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 200 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual